Business
MiNK Therapeutics Corporate Update and First Quarter 2022 Financial Report
Clinical updates from solid tumor cancers and ARDS with allo-agenT-797 are on track for 2H 2022GMP manufacturing launch in 1H 2022 with target 10,000
About this update from Mink Therapeutics, Inc.
[{"type":"text","content":"Clinical updates from solid tumor cancers and ARDS with allo-agenT-797 are on track for 2H 2022GMP manufacturing launch in 1H 2022 with target 10,000 doses/yrBCMA-CAR-iNKT and stromal-CAR-iNKT preclinical results 2H 2022Ended First Quarter with $34.7M in cash with a projected 2022 cash burn of $16.8M NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today reported financial results for the first quarter 2022 and provided a corporate business update. “MiNK has made important progress in advancing our ongoing clinical programs, manufacturing platform, and differentiated pipeline,” said Jennifer Buell, Ph.D., President and CEO of MiNK Therapeutics. “We are on track for data readouts this year designed to underscore the characteristics of iNKT cells and the potential to expand durability of clinical benefit with favorable tolerability, including the elimination of toxic lymphodepletion.” Recent Business Progress and Future Milestones AgenT-797 +/- CPIs in Solid Tumors: Phase 1 study evaluating agenT-797, without lymphodepletion, alone and in combination with approved anti-PD-1 in solid tumor cancers has cleared early dose cohorts and is in expansion cohorts. On track for data readouts in 2H 2022. AgenT-797 in Multiple Myeloma: Accrual continues in phase 1 study of agenT-797, without lymphodepletion, in relapsed/refractory multiple myeloma. Completed early dose cohorts with early biomarker signals of activity and no dose limiting toxicities. Data updates on track for 2H 2022. Acute respiratory distress syndrome (ARDS) program: Phase 1/2 expansion initiated and underway evaluating agenT-797 in severe ARDS secondary to COVID-19 and influenza. Next generation iNKT platforms (iNKT engagers, CAR-iNKT platforms, TCRs): IND enabling studies underway for BCMA-CAR-iNKT and stromal targeting CAR-iNKT (undisclosed target). Presentation of preclinical data planned for 2H 2022.Advancing differentiated and novel programs for TCRs (IND ready program) and iNKT cell engagers. MiNK Internal Manufacturing Capabilities Ready for GMP Launch: Launched automated closed system manufacturing process in-house f...